Zymeworks stock price target reaffirmed at $32 by Citizens

Citizens reiterated a Market Outperform rating and $32 price target for Zymeworks (ZYME), citing clinical data on ZW191 and a Roche licensing deal. The stock is up 59% year-over-year. Zymeworks has $627.5M in cash and is conducting a share buyback. Other analysts have raised price targets, with Jefferies at $52 and H.C. Wainwright at $55.

Original reporting
Published Oct 26, 2026, 9:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

The reaffirmed target and new deals suggest a short‑term bullish bias, but investors should monitor trial progress and integration execution.

02

Market read

The news provides fresh material for traders focusing on biotech catalysts and could drive Zymeworks' share price higher.

03

What to watch

Potential dilution from the share buyback program and integration risk of Theravance.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

The piece is an analyst note summarizing recent corporate developments for Zymeworks, a NASDAQ‑listed biotech.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Citizens reaffirmed a $32 price target for Zymeworks after reporting a licensing deal with Roche and the completion of the Theravance Biopharma acquisition.

Expected impact

likely upward pressure as market prices in the new cash flow and milestone potential.

Evidence & confidence

The article discloses fresh commercial agreements and a strategic acquisition, both of which are material for a biotech with a $28 share price.

Market effects

Strengthens the biotech sector's outlook on antibody‑drug conjugates and licensing partnerships.

Positive for North American biotech equities.

Highlights continued interest from large pharma in niche oncology assets.

Counterpoint

The licensing milestones may be priced in already; execution risk on Phase 1b could temper upside.

Key entities

  • Zymeworks Inc.

    Biotech firm developing antibody‑drug conjugates.

  • Roche

    Pharma partner licensing ZW209.

  • Theravance Biopharma

    Acquired by Zymeworks.

Related articles

$ZYMEMed

Zymeworks Authorized To Buy Back Up To $200 Mln Of Shares

Zymeworks' board approved a $200M share buyback program, starting before 2026 and ending in 2028, funded by cash reserves and expected inflows, including Roche fees and a potential milestone payment. The company completed a $125M buyback earlier this year. Shares closed at $26.24 on Friday.

$ZYMEHighAI 9/10

Zymeworks Inc. (ZYME): Reports Third Quarter 2026 Financial Results

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results • 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 m

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$ZYMEMedAI 9/10

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.

$ZYMEMed

Truist raises Zymeworks stock price target on pipeline progress

Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.